153 related articles for article (PubMed ID: 32880071)
1. Parkinson's disease laterality: a
Roussakis AA; Zeng Z; Lao-Kaim NP; Martin-Bastida A; Piccini P;
J Neurol; 2021 Feb; 268(2):582-589. PubMed ID: 32880071
[TBL] [Abstract][Full Text] [Related]
2.
Li W; Lao-Kaim NP; Roussakis AA; Martín-Bastida A; Valle-Guzman N; Paul G; Loane C; Widner H; Politis M; Foltynie T; Barker RA; Piccini P
Mov Disord; 2018 Jan; 33(1):117-127. PubMed ID: 29082547
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
[TBL] [Abstract][Full Text] [Related]
4. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal DAT changes measured with [
Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease.
Delva A; Van Laere K; Vandenberghe W
Mov Disord; 2022 Sep; 37(9):1883-1892. PubMed ID: 35819412
[TBL] [Abstract][Full Text] [Related]
7. Quantification and discriminative power of
Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633
[TBL] [Abstract][Full Text] [Related]
8. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
9. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
[TBL] [Abstract][Full Text] [Related]
10. Patterns of striatal dopamine depletion and motor deficits in de novo Parkinson's disease.
Jeong SH; Park CW; Lee HS; Kim YJ; Yun M; Lee PH; Sohn YH; Chung SJ
J Neural Transm (Vienna); 2023 Jan; 130(1):19-28. PubMed ID: 36462096
[TBL] [Abstract][Full Text] [Related]
11. Associations of striatal dopamine transporter binding with motor and non-motor symptoms in early Parkinson's disease.
Yang Z; Xie Y; Dou K; Yang L; Xie A
Clin Transl Sci; 2023 Jun; 16(6):1021-1038. PubMed ID: 36915231
[TBL] [Abstract][Full Text] [Related]
12. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
[TBL] [Abstract][Full Text] [Related]
13. Dopamine transporter imaging with [
Jakobson Mo S; Axelsson J; Jonasson L; Larsson A; Ögren MJ; Ögren M; Varrone A; Eriksson L; Bäckström D; Af Bjerkén S; Linder J; Riklund K
EJNMMI Res; 2018 Nov; 8(1):100. PubMed ID: 30443684
[TBL] [Abstract][Full Text] [Related]
14. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study.
Liu SY; Wu JJ; Zhao J; Huang SF; Wang YX; Ge JJ; Wu P; Zuo CT; Ding ZT; Wang J
Parkinsonism Relat Disord; 2015 Dec; 21(12):1448-53. PubMed ID: 26559130
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
Fiorenzato E; Antonini A; Bisiacchi P; Weis L; Biundo R
Mov Disord; 2021 Oct; 36(10):2303-2313. PubMed ID: 34124799
[TBL] [Abstract][Full Text] [Related]
16. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
[TBL] [Abstract][Full Text] [Related]
17. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
[TBL] [Abstract][Full Text] [Related]
18. Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density.
Kawaguchi H; Shimada H; Kodaka F; Suzuki M; Shinotoh H; Hirano S; Kershaw J; Inoue Y; Nakamura M; Sasai T; Kobayashi M; Suhara T; Ito H
PLoS One; 2016; 11(3):e0151191. PubMed ID: 26954690
[TBL] [Abstract][Full Text] [Related]
19. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
[TBL] [Abstract][Full Text] [Related]
20. Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's disease.
Mito Y; Yabe I; Yaguchi H; Sato C; Takei T; Terae S; Tajima Y
Clin Neurol Neurosurg; 2020 Sep; 196():105960. PubMed ID: 32593043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
